Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 3
Submit an article Journal homepage
72
Views
16
CrossRef citations to date
0
Altmetric
Review

Antiviral therapy of influenza

Jonathan A McCullers Department of Infectious Diseases, St. Jude Children’s Research Hospital, 332 North Lauderdale Street, Memphis, TN38105-2794, USA. [email protected]
Pages 305-312 | Published online: 22 Apr 2005

Bibliography

  • STOHR K: Preventing and treating influenza. BE Med. J. (2003) 326:1223–1224.
  • WEYCKER D, EDELSBERG J, ELIZABETH HM et al.: Population-wide benefits of routine vaccination of children against influenza. Vaccine (2005) 23:1284–1293.
  • MONTO AS, KIOUMEHR F: The Tecumseh Study of Respiratory Illness IX. Occurence of influenza in the community, 1966–1971. Am. J. Epidennol. (1975) 102:553–563.
  • GLEZEN WP: Serious morbidity and mortality associated with influenza epidemics. Epidennol. Rev. (1982) 4:25–44.
  • MELTZER MI, COX NJ, FUKUDA K: The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis. (1999) 5:659–671.
  • POTTER CW: Chronicle of influenza pandemics. Nicholson KG, Webster RG and Hay AJ (Eds). Blackwell Scientific Publications, London, UK (1998):3–18.
  • WEBBY RJ, WEBSTER RG: Are we ready for pandemic influenza? Science (2003) 302:1519–1522.
  • •Current overview of pandemic preparedness.
  • KAWAOKA Y, KRAUSS S, WEBSTER RG: Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. Virol. (1989) 63:4603–4608.
  • DE JONG JC, CLAAS EC, OSTERHAUS AD, WEBSTER RG, LIM WL: A pandemic warning? Nature (1997) 389:554.
  • LI KS, GUAN Y, WANG J et al: Genesis ofa highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 430:209–213.
  • FOUCHIER RA, SCHNEEBERGER PM, ROZENDAAL FW et al: Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci USA (2004) 101:1356–1361.
  • HARPER SA, FUKUDA K, UYEKI TM, COX NJ, BRIDGES CB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2004) 53:1–40.
  • WEIS W, BROWN JH, CUSACK S, PAULSON JC, SKEHEL JJ, WILEY DC: Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature (1988) 333:426–431.
  • CARR CM, KIM PS: A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (1993) 73:823–832.
  • PINTO LH, HOLSINGER LJ, LAMB RA: Influenza virus M2 protein has ion channel activity. Cell (1992) 69:517–528.
  • HAY AJ, WOLSTENHOLME AJ, SKEHEL JJ, SMITH MH: The molecular-basis of the specific anti-influenza action of amantadine. EMBO J. (1985) 4:3021–3024.
  • •Defines the mechanism of action of M2 inhibitors and describes the mutations required for resistance.
  • TOOGOOD PL, GALLIKER PK, GLICK GD, KNOWLES JR: Monovalent sialosides that bind tightly to influenza A virus. J. Med. Chem. (1991) 34:3138–3140.
  • CHOI SK, MAMMEN M, WHITESIDES GM: Monomeric inhibitors of influenza neuraminidase enhance the hemagglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups. Chem. Biol. (1996) 3:97–104.
  • O'KEEFE BR, SMEE DF, TURPIN JA et al: Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. (2003) 47:2518–2525.
  • LUO G, TORRI A, HARTE WE et al: Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J. Virol. (1997) 71:4062–4070.
  • COMBRINK KD, GULGEZE HB, YU KL et al.: Salicylamide inhibitors of influenza virus fusion. Bioorg. Med. Chem. Lett. (2000) 10:1649–1652.
  • BODIAN DL, YAMASAKI RB, BUS WELL RL, STEARNS JF, WHITE JM, KUNTZ ID: Inhibition of the fusion-inducing conformational change of influenza haemagglutinin by benzoquinones and hydroquinones. Biochemistry (1993) 32:2967–2978.
  • YU KL, TORRI AF, LUO G et al.: Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethy1-5-hydroxy- cyclohexylmethylamine. Bioorg. Med. Chem. Lett. (2002) 12:3379–3382.
  • HOFFMAN LR, KUNTZ ID, WHITE JM: Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J. VIM]. (1997) 71:8808–8820.
  • DETJEN BM, ST ANGELO C, KATZE MG, KRUG RM: The three influenza virus polymerase (P) proteins not associated with viral nucleocapsids in the infected cell are in the form of a complex. J. VIM]. (1987) 61:16–22.
  • KRUG RM: Priming of influenza viral RNA transcription by capped heterologous RNAs. Curr. Top. Microbiol. Immunol. (1981) 93:125–149.
  • SHAPIRO GI, KRUG RM: Influenza virus RNA replication in vitro: synthesis of viral template RNAs and virion RNAs in the absence of an added primer. Virol. (1988) 62:2285–2290.
  • DE CLERCQ E: Antiviral drugs in currentclinical use. J. Clin. Virol. (2004) 30:115–133.
  • HASTINGS JC, SELNICK H, WOLANSKI B, TOMASSINI JE: Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob. Agents Chemother. (1996) 40:1304–1307.
  • PARKES KE, ERMERT P, FASSLER J et al.: Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J. Med. Chem. (2003) 46:1153–1164.
  • GE Q, FILIP L, BAI A, NGUYEN T, EISEN HN, CHEN J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA (2004) 101:8676–8681.
  • TOMPKINS SM, LO CY, TUMPEY TM, EPSTEIN SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA (2004) 101:8682–8686.
  • LAMB RA, KRUG RM: Orthomyxoviridae: the viruses and their replication. In: Fields Virology Knipe DM and Howley PM (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2001):1487–1531.
  • PALESE P, TOBITA K, UEDA M, COMPANS RW: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology (1974) 61:397–410.
  • VON ITZSTEIN M, DYASON JC, OLIVER SW et al.: A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs." Med. Chem. (1996) 39:388–391.
  • •Describes the rational design of zanamivir, the first inhibitor in the NAT class.
  • GUBAREVA LV, KAISER L, HAYDEN FG: Influenza virus neuraminidase inhibitors. Lancet (2000) 355:827–835.
  • •Excellent review of the development and pharmacokinetics of, and potential for resistance to, the NAIs.
  • LUND JM, ALEXOPOULOU L, SATO A et al.: Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. ScL USA (2004) 101:5598–5603.
  • KRUG RM, YUAN W, NOAH DL, LATHAM AG: Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology (2003) 309:181–189.
  • GARCIA-SASTRE A, EGOROV A, MATASSOV D et al: Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 252:324–330.
  • CHEN Z, LI Y, KRUG RM: Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J. (1999) 18:2273–2283.
  • LENEVA IA, HAY AJ. The mechanism of action of arbidol against influenza virus. Selection and characterization of arbidol-resistant mutants. American Society for Virology 18th Annual Meeting. Amherst, USA (1999):W27–W36.
  • BROOKS MJ, SASADEUSZ JJ, TANNOCK GA: Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr. Opin. Pulm. Med. (2004) 10:197–203.
  • READING PC, MOREY LS, CROUCH EC, ANDERS EM: Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J. Virol. (1997) 71:8204–8212.
  • MONTO AS: The role of antivirals in thecontrol of influenza. Vaccine (2003) 21:1796–1800.
  • •Concise overview of the clinical uses of influenza antivirals.
  • WU MJ, ING TS, SOUNG LS, DAUGIRDAS JT, HANO JE, GANDHI VC: Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin. Nephrol. (1982) 17:19–23.
  • VAN VORIS LP, BETTS RF, HAYDEN FG, CHRISTMAS WA, DOUGLAS RG Jr: Successful treatment of naturally occurring influenza A/U55R/77 H1N1. /AMA (1981) 245:1128–1131.
  • MONTO AS, ARDEN NH: Implications of viral resistance to amantadine in control of influenza A. Clin. Infect. Dis. (1992) 15:362–367.
  • STAMATIOU G, KOLOCOURIS A, KOLOCOURIS N et al: Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups. Bioorg. Med. Chem. Lett. (2001) 11:2137–2142.
  • SKOLIMOWSKI J, KOCHMAN A, GEBICKA L, METODIEWA D: Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical. Bioorg. Med. Chem. (2003) 11:3529–3539.
  • DOLIN R, REICHMAN RC, MADORE HP, MAYNARD R, LINTON PN, WEBBER-JONES J: A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl. J. Med. (1982) 307:580–584.
  • GALBRAITH AW, OXFORD JS, SCHILD GC, WATSON GI: Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet (1969) 2:1026–1028.
  • HAYDEN FG, MONTO AS: Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob. Agents Chemother. (1986) 29:339–341.
  • HALL CB, DOLIN R, GALA CL et al.: Children with influenza A infection: treatment with rimantadine. Pediatrics (1987) 80:275–282.
  • HAYDEN FG, BELSHE RB, CLOVER RD, HAY AJ, OAKES MG, SOO W: Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl. J. Med. (1989) 321:1696–1702.
  • BELSHE RB, SMITH MH, HALL CB, BETTS R, HAY AJ: Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. Virol. (1988) 62:1508–1512.
  • ASTRAHAN P, KASS I, COOPER MA, ARKIN IT: A novel method of resistance for influenza against a channel-blocking antiviral drug. Proteins (2004) 55:251–257.
  • •Provides insight into a novel mechanism for resistance to the M2 inhibitors.
  • BELSHE RB, BURK B, NEWMAN F, CERRUTI RL, SIM IS: Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. (1989) 159:430–435.
  • GREGORY V, LIM W, CAMERON K et al: Infection of a child in Hong Kong by an influenza A H3N2 virus closely related to viruses circulating in European pigs. Gen. Virol. (2001) 82:1397–1406.
  • GUBAREVA LV, PENN CR, WEBSTER RG: Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N acetylneuraminic acid. Virology (1995) 212:323–330.
  • CASS LM, EFTHYMIOPOULOS C, BYE A: Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. (1999) 36\(Suppl. 1):1–11.
  • HAYDEN FG, TREANOR JJ, FRITZ RS et al: Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 282:1240–1246.
  • •Phase III trial evaluating oseltamivir for prevention and treatment of influenza.
  • GUBAREVA LV: Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. (2004) 103:199–203.
  • KISO M, MITAMURA K, SAKAI -TAGAWA Y et al.: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet (2004) 364:759–765.
  • HAYDEN FG, ATMAR RL, SCHILLING M et al.: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl. J. Med. (1999) 341:1336–1343.
  • WELLIVER R, MONTO AS, CAREWICZ 0 et al: Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. "AMA (2001) 285:748–754.
  • HAYDEN FG, BELSHE R, VILLANUEVA C et al: Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis. (2004) 189:440–449.
  • HAYDEN FG, OSTERHAUS AD, TREANOR JJ et al: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl. J. Med. (1997) 337:874–880.
  • TREANOR JJ, HAYDEN FG, VROOMAN PS et al: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. "AMA (2000) 283:1016–1024.
  • GUBAREVA LV, WEBSTER RG, HAYDEN FG: Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Cheinother. (2001) 45:3403–3408.
  • GOVORKOVA EA, LENEVA IA, GOLOUBEVA OG, BUSH K, WEBSTER RG: Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Cheinother. (2001) 45:2723–2732.
  • SIMONSEN L: The global impact of influenza on morbidity and mortality. Vaccine (1999) 17\(Suppl. 1):53–S10.
  • MICHELOW IC, OLSEN K, LOZANO J et al.: Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics (2004) 113:701–707.
  • HEIKKINEN T, THINT M, CHONMAITREE T: Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl. J. Med. (1999) 340:260–264.
  • McCULLERS JA, FACCHINI S, CHESNEY PJ, WEBSTER RG: Influenza B virus encephalitis. Clin. Infect. Dis. (1999) 28:898–900.
  • Update: influenza activity-United States, 2003-04 season. MMWR Morb. Mortal. Wkly Rep. (2003) 52:1197–1202.
  • MORISHIMA T, TOGASHI T, YOKOTA S et al.: Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect. Dis. (2002) 35:512–517.
  • NYQUIST AC, GONZALES R, STEINER JF, SANDE MA: Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. "AMA (1998) 279:875–877.
  • GONZALES R, SANDE MA: Uncomplicated acute bronchitis. Ann. Intern. Med. (2000) 133:981–991.
  • McCULLERS JA, BARTMESS KC: Role ofneuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. ./. Infect. Dis. (2003) 187:1000–1009.
  • McCULLERS JA: Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J. Infect. Dis. (2004) 190:519–526.
  • WHITLEY RJ, HAYDEN FG, REISINGER KS et al: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. (2001) 20:127–133.
  • KAISER L, WAT C, MILLS T, MAHONEY P, WARD P, HAYDEN F: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. (2003) 163:1667–1672.
  • COOPER NJ, SUTTON AJ, ABRAMS KR, WAILOO A, TURNER D, NICHOLSON KG: Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. Br. Med. J. (2003) 326:1235–1241.
  • DOYLE WJ, SKONER DP, ALPER CM et al: Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. I Infect. Dis. (1998) 177:1260–1265.
  • STRAUMANIS JP, TAPIA MD, KING JC: Influenza B infection associated with encephalitis: treatment with oseltamivir. Pediatr. Infect. Dis. J. (2002) 21:173–175.
  • SUGAYA N, MIURA M: Amantadine therapy for influenza type A-associated encephalopathy. Pediatr. Infect. Dis. I (1999) 18:734.
  • Update: influenza activity-United States and worldwide, May-October 2004. MMWR Morb. Mortal. Wkly Rep. (2004) 53:993–995.
  • KAISER J: Influenza: girding for disaster.Facing down pandemic flu, the world's defenses are weak. Science (2004) 306:394–397.
  • LONGINI IM, JR., HALLORAN ME, NIZAM A, YANG Y: Containing pandemic influenza with antiviral agents. Ain. Epideiniol (2004) 159:623–633.
  • •Model methods of controlling pandemic spread of influenza using antivirals.
  • CIANCI C, KRYSTAL M: Development of antivirals against influenza. Expert Opin. Investig. Drugs (1998) 7:149–165.
  • •Detailed review of the influenza life cycle and targets for inhibition by antivirals.
  • http://www.whoint/csr/disease/ avian_influenza/en/ WHO avian influenza website.

Websites

  • http://www.who.int/csr/disease/influenza/ pandemic/en/ WHO pandemic preparedness website.
  • http://www.dhhs.govinvpo/pandemicplan/ United States Health and Human Services pandemic preparedness website.
  • ••Thorough treatment of pandemic planningis expected to evolve with continued input from experts.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.